DOCSLIB.ORG

Treatment Shortening for (Drug-Susceptible) Pulmonary TB: Building

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Treatment Shortening for (Drug-Susceptible) Pulmonary TB: Building Treatment shortening for (drug-susceptible) pulmonary TB: Building a case for rifapentine Susan Dorman, MD XXI Jornadas Internacionales sobre Tuberculosis 20 November 2017 Disclosures • Sanofi aventis donated rifapentine to the CDC for some of the studies described in this talk Need for Shorter Treatment for DS-TB (in addition to improving access to, delivery of TB care) • Shorter, highly potent regimens have potential to: • Increase adherence, decrease default rates • Decrease drug resistance • Decrease TB Control Program costs • Strategies for developing shorter regimens • New drugs • Optimize use of existing drugs Existing drugs that may not be used optimally • Rifamycins • Is 10 mg/kg the optimal dose for rifampin? • Is rifampin the optimal drug in its class? • Fluoroquinolones • Which fluoroquinolone? • As replacement for ethambutol? • As replacement for isoniazid? • Pyrazinamide • How to get drug into more bacteria • How to minimize toxicity and maximize activity • Linezolid, β-lactams, others Rifamycins Rifamycins •Inhibit bacterial DNA-dependent RNA polymerase •Key “sterilizing” component of TB tx •Rifampin, rifapentine, rifabutin, rifalazil Current use of rifampin and the case for pharmacodynamic (PD) optimization A lot of Evidence of MED in humans PD in mice3 bacteria • Early bactericidal activity2 RIF dose n EBA0-2 300 mg 3 0.06 600 mg 8 0.19 1200 mg 8 0.41 • In DAILY combo therapy with INH: Doses <9 mg/kg associated with positive sputum cx at 8, 16, 20 wks Few/no bacteria 1 Jindani et al, Am Rev Respir Dis 1980;121:939 2 Long et al, Am Rev Respir Dis 1970;119;879 3 Jayaram et al, AAC (2003); 47:2118 Current use of rifampin and the case for pharmacodynamic (PD) optimization A lot of Evidence of MED in humans PD in mice bacteria • Early bactericidal activity2 RIF dose n EBA0-2 300 mg 3 0.06 600 mg 8 0.19 1200 mg 8 0.41 Range of human AUC/MIC after 600 mg oral dose • In DAILY combo therapy with INH: Doses <9 mg/kg associated with positive sputum cx at 8, 16, 20 wks Few/no bacteria 1 Jindani et al, Am Rev Respir Dis 1980;121:939 2 Long et al, Am Rev Respir Dis 1970;119;879 3 Jayaram et al, AAC (2003); 47:2118 Existing drugs that may not be used optimally • Rifamycins • Is 10 mg/kg the optimal dose for rifampicin? • Is rifampicin the optimal drug in its class? • Fluoroquinolones • Which fluoroquinolone? • As replacement for ethambutol? • As replacement for isoniazid? • Pyrazinamide • How to get drug into more bacteria • How to minimize toxicity and maximize activity • Linezolid, β-lactams, others rifapentine rifampicin Rifapentine (RPT, P) Half-life = 14-18 h (vs. 2-4 for RIF) MIC90 = 0.06 mg/ml (vs. 0.25 for RIF) Developed as a rifamycin for highly intermittent (600 mg once or twice per week) active TB treatment; US FDA approved for this indication in 1998, but activity of these intermittent regimens is not sufficient for their use in patients at high risk for treatment failure Preclinical: DAILY rifapentine is highly active in mouse model of TB R, rifampin 8 R10HZ Proportion (%) of mice relapsing after Rx for: P, rifapent in e Regimen 7 R20HZ 8 wks 10 wks 12 wks 6 R40HZ R10 HZ Not Done Not Done 100% (15/15) 5 P10HZ R20 HZ Not Done 100% (15/15) 67% (10/15) 4 P20HZ R40 HZ Not Done 27% (4/15) 0% (0/15) 3 P10 HZ 100% (15/15) 33% (5/15) 0% (0/15) 2 P20 HZ 40% (6/15) 0% (0/15) 1 0 0 2 4 6 8 10 12 Replacing RIFAMPIN 10 mg/kg/d with Treatment duration (weeks) RIFAPENTINE 10 mg/kg/d: • increases bactericidal & sterilizing activity • halves the time needed for cure From Nuermberger et al ClinicalTBTC S29B: Multiple Phase dose 1: RPT Safety PK and PK of escalating rifapentine daily doses in healthy volunteers 5 mg/kg RPT 10 mg/kg RPT 15 mg/kg RPT 20 mg/kg RPT No evidence of dose-dependent increase in frequency of known rifamycin-associated toxicities, e.g. hepatotoxicity or cytopenias Max tolerated dose at least 20 mg/kg/d. 10 20 30 40 50 60 70 Time from dose (h) Dooley et al; Clin Pharmacol Ther 2012;91:881 Clinical Phase 2: TBTC Study ‘29X’ STUDY OBJECTIVE For regimens that include “high” doses of RPT (in addition to H+Z+E) administered daily during intensive phase treatment of smear positive, drug susceptible pulmonary TB: • Determine safety & tolerability • Estimate antimicrobial activity, using a surrogate endpoint for ‘cure’ • PK/PD relationships • Which PK parameter is associated with effect or toxicity? • For the key PK parameter, what range should we target? • Are there covariates that influence that PK parameter? • What strategies can we use to get the most people at that PK parameter target Sputum smear (+) PTB suspect Phase 2 Randomization (n=320) RPT 20 mg/kg RPT 15 mg/kg RPT 10 mg/kg RIF 10 mg/kg RPT placebo RPT placebo INH+PZA+EMB INH+PZA+EMB INH+PZA+EMB INH+PZA+EMB 7/7 for 8 weeks 7/7 for 8 weeks 7/7 for 8 weeks 7/7 for 8 weeks Study visits every 2 weeks for safety assessments & sputum culture Double-blind with respect to RPT dose, but not RPT vs RIF RPT given with high-fat food to maximize absorption ASSESS FOR PRIMARY ENDPOINTS: Tolerability/safety: discontinuations, AEs Efficacy (surrogates): % culture neg at week 8, time to stable cx conversion ATS/CDC/IDSA-recommended continuation phase regimen Current TB treatment “intensive phase” “continuation phase” RIF 10 mg/kg/d RPT 10 mg/kg/d isoniazid rifampin isoniazid RPT 15 mg/kg/d pyrazinamide rifampin 10 mg/kg ethambutol RPT 20 mg/kg/d 1 2 3 4 5 6 months Sites enrolling in SettingTBTC Study 29 and 29x Phase 2 TB Trials Consortium Enrollment Phase 2 • Inclusion criteria (summary) • Age 18 years or older • Sputum smear (+) PTB suspect • < 5 days TB tx, prior 6 months • HIV testing; those on ART excluded (drug-drug interactions) • Karnofsky > 60 •AST <3x ULN • Informed consent • Randomization stratified by • Enrollment site • baseline cavitation, yes vs. no 801 Not enrolled: 1135 Screened Phase 2 Refused (127) Not eligible (573) Other or unknown (101) 334 Enrolled 80 not eligible for MITT: 334 Intention-to-Treat • Did not grow Mtb (6) • Resistant to INH, rifamycins and/or analysis PZA (44) • Other (30) 254 Modified Intention-to- 19 not eligible for Per-Protocol: Treat analysis • Drug toxicity led to d/c regimen (5) • Died (2) • Withdrew consent or physician advised to d/c regimen (7) 235 Per Protocol analysis • Contaminated week 8 cx (1 • Other (2) Clinical Phase 2: TBTC Study 29X Phase 2 Results: Study Population (ITT) Assigned treatment arm --> RIF 10 RPT 10 RPT 15 RPT 20 N=85 N=87 N=81 N=81 Median age (range) 33 (19,78) 29 (19,66) 31 (18,69) 31 (19,70) Median weight (range) 54 (41,77) 54 (40,76) 55 (40,81) 54 (41,82) Male (%) 55 (65) 63 (72) 58 (72) 54 (67) Cavitary pulmonary TB (%) 69 (81) 67 (77) 61 (75) 60 (74) HIV-positive (%) 5 (6) 6 (7) 4 (5) 11 (14) Enrolled at African site (%) 45 (53) 49 (56) 48 (59) 48 (59) *A well-tolerated regimen was pre-defined as one for which the 90% one-sided confidence limit of the Clinical Phase 2: TBTC Study 29X % of participants who permanently discontinued Results: Tolerability (ITT) that regimen was < 30% Assigned treatment arm ---> RIF CTRL RPT 10 RPT 15 RPT 20 N=85 N=87 N=81 N=81 Regimen permanently discontinued 11 5 5 9 (12.9%) (5.7%) (6.2%) (11.1%) Upper bound of 90% one-sided CL* 19.0 10.5 11.3 17.1 based on microbiology 4 2 3 3 death 0 0 1 1 toxicityother than death 3 0 1 2 w/draw consent, refuse to continue 23 0 0 Other 2 0 0 3 Safety: No differences in adverse events (number, type, severity) between arms % of participants whose sputum is Mtb negative at the end of intensive phase treatment (MITT), by ASSIGNED TREATMENT ARM RIF RPT 10 mg/kg RPT 15 mg/kg RPT 20 mg/kg SOLID CX (n/n) 81.3 (52/64) 92.5 (62/67) 89.4 (59/66) 94.7 (54/57) % difference vs. RIF 11.3 8.1 13.5 (95% CI) (-1.7, 24.3) (-5.5, 21.8) (0.7, 26.3) value 0.10 0.14 0.05 LIQUID CX (n/n) 56.3 (36/64) 74.6 (50/67) 69.7 (46/66) 82.5 (47/57) % difference vs. RIF 18.4 13.5 26.2 (95% CI) (0.8, 35.9) (-4.5, 31.4) (8.9, 43.5) value 0.04 0.16 <0.01 RIF in S29: solid 79.2%, liquid 62.6% % of participants whose sputum is Mtb negative at the end of intensive phase treatment (MITT), by RIFAPENTINE AUC TERTILE low AUC medium AUC high AUC RIF RPT RPT RPT AUC < 297 AUC 297-461 AUC > 461 SOLID CX (n/n) 81.3 (52/64) 85.5 (47/55) 96.7 (58/60) 93.3 (70/75) % difference vs. RIF 4.2 15.4 12.1 (95% CI) (-10.8, 19.2) (3.2, 27.6) (-0.5, 24.6) value 0.27 <0.01 0.02 LIQUID CX (n/n) 56.3 (36/64) 56.4 (31/55) 86.7 (52/60) 80.0 (60/75) % difference vs. RIF 0.1 30.4 23.8 (95% CI) (-19.5, 19.7) (13.9, 46.9) (7.1, 40.4) value 0.50 <0.01 <0.01 RIF in S29: solid 79.2%, liquid 62.6% Clinical Phase 2:TBTC Study 29X Phase 2 Arm- vs.
Load more

Recommended publications
  • WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/11 (2006.01) A61K 38/08 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2015/031213 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 15 May 2015 (15.05.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/000,43 1 19 May 2014 (19.05.2014) US kind of regional protection available): ARIPO (BW, GH, 62/129,746 6 March 2015 (06.03.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors; and TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicants : GELLER, Bruce, L.
    [Show full text]
  • CLINICAL USE of RIFABUTIN, a RIFAMYCIN-CLASS ANTIBIOTIC, for the TREATMENT of TUBERCULOSIS (A Supplement to the 2008 Revision Of“ Standards for Tuberculosis Care”)
    Kekkaku Vol. 86, No. 1: 43, 2011 43 CLINICAL USE OF RIFABUTIN, A RIFAMYCIN-CLASS ANTIBIOTIC, FOR THE TREATMENT OF TUBERCULOSIS (A supplement to the 2008 revision of“ Standards for tuberculosis care”) August, 2008 The Treatment Committee of the Japanese Society for Tuberculosis The Treatment Committee of the Japanese Society for [Dosage and administration of rifabutin] Tuberculosis published statements on the“ Standards for Rifabutin, 5 mg/kg in body weight/day, maximum 300 mg/ tuberculosis care” in April 2008. Therein we referred to day, once daily. rifampicin as follows“; Use of rifampicin requires attention The dosage of rifabutin can be increased up to the maximum because of the interactions with a number of other drugs. daily dose of 450 mg in cases where decreased rifabutin serum Particularly for HIV-infected patients who need antiviral levels are expected due to anti-HIV drugs such as efavirenz, drugs, the replacement of rifampicin by rifabutin should be and in other cases if necessary. considered”. Rifabutin, belonging to rifamycin-class antibiotics In non-HIV-infected patients, rifabutin can be used for like rifampicin, causes less significant drug-drug interactions intermittent treatment with a regimen of twice or three times a than rifampicin, and can be used in combination with antiviral week, with the same dosage as daily administration. drugs mentioned above. In July 2008, rifabutin was approved as antituberculous drug, and is expected to be added to the drug [Important points for use of rifabutin] price listing in the near future*. Therefore, to the published (1) Rifabutin causes drug interactions due to induction of opinions, we add new statements concerning the use of rifabutin hepatic enzyme though less significantly than rifampicin.
    [Show full text]
  • Rifabutin (Mycobutin) Reference Number: HIM.PA.12 Effective Date: 09.04.18 Last Review Date: 11.19 Revision Log Line of Business: HIM
    Clinical Policy: Rifabutin (Mycobutin) Reference Number: HIM.PA.12 Effective Date: 09.04.18 Last Review Date: 11.19 Revision Log Line of Business: HIM See Important Reminder at the end of this policy for important regulatory and legal information. Description Rifabutin (Mycobutin®) is a derivative of rifamycin, an antimycobacterial agent. FDA Approved Indication(s) Mycobutin is indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Mycobutin is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Mycobacterium avium Complex Prophylaxis (must meet all): 1. Prescribed by or in consultation with an HIV or infectious disease specialist; 2. Age ≥ 18 years; 3. Failure of azithromycin or clarithromycin, unless contraindicated or clinically significant adverse effects are experienced; 4. Dose does not exceed 300 mg per day. Approval duration: 12 months B. Tuberculosis (must meet all): 1. Diagnosis of tuberculosis infection; 2. Prescribed by or in consultation with an HIV or infectious disease specialist; 3. Documentation of current treatment with protease inhibitors or non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV infection; 4. Age ≥ 18 years; 5. Dose does not exceed 5 mg/kg per day. Approval duration: 12 months C. Other diagnoses/indications 1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • RIFABUTIN Rifabutin Must Be Taken Regularly to Higher Risk of Bacterial Infection), Or Be Effective and to Prevent the Anemia (A Reduced Number of Red
    RIFABUTIN Rifabutin must be taken regularly to higher risk of bacterial infection), or be effective and to prevent the anemia (a reduced number of red development of resistance. Take all blood cells that can make you feel Other NAMES: Mycobutin of your doses even if you begin to tired and short of breath). In rare feel better. cases it can also cause WHY is this drug prescribed? thrombocytopenia (a reduced What should you do if you number of platelets so that you bleed Rifabutin is an antibacterial drug used to FORGET a dose? or bruise more easily), or changes in prevent or treat Mycobacterium avium liver function . Blood tests will be complex (MAC) infection. When used If you miss a dose of rifabutin, take it done regularly to check for any to treat MAC, it is usually used in as soon as possible. However, if it is changes in these values. Inform combination with other agents. time for your next dose, do not your doctor or pharmacist if you have double the dose, just carry on with symptoms such as fever, chills, Rifabutin may also be used to treat other your regular schedule. shortness of breath, racing types of infections, including heartbeat, fatigue, bleeding or tuberculosis. What ADVERSE EFFECTS can this bruising. drug cause? What should you do HOW should this drug be taken? about them? Rifabutin may cause uveitis (an inflammation of the eye causing When used to prevent or treat MAC, the Most adverse effects of rifabutin are pain, redness and loss of vision). It usual dose is 300mg once daily.
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • E3 Appendix 1 (Part 1 of 2): Search Strategy Used in MEDLINE
    This single copy is for your personal, non-commercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, contact CJHP at [email protected] Appendix 1 (part 1 of 2): Search strategy used in MEDLINE # Searches 1 exp *anti-bacterial agents/ or (antimicrobial* or antibacterial* or antibiotic* or antiinfective* or anti-microbial* or anti-bacterial* or anti-biotic* or anti- infective* or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or clindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).kf,kw,ti. or (antimicrobial or antibacterial or antiinfective or anti-microbial or anti-bacterial or anti-infective or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or c lindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).ab. /freq=2 2 alamethicin/ or amdinocillin/ or amdinocillin pivoxil/ or amikacin/ or amoxicillin/ or amphotericin b/ or ampicillin/ or anisomycin/ or antimycin a/ or aurodox/ or azithromycin/ or azlocillin/ or aztreonam/ or bacitracin/ or bacteriocins/ or bambermycins/ or bongkrekic acid/ or brefeldin a/ or butirosin sulfate/ or calcimycin/ or candicidin/ or capreomycin/ or carbenicillin/ or carfecillin/ or cefaclor/ or cefadroxil/ or cefamandole/ or cefatrizine/ or cefazolin/ or cefixime/ or cefmenoxime/ or cefmetazole/ or cefonicid/ or cefoperazone/
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Information for the User Mycobutin®150Mg Capsules Rifabutin Read All
    Package Leaflet: I nformation for the user Mycobutin ®150mg capsules rifabutin Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Mycobutin is and what it is used for 2. What you need to know before you take Mycobutin 3. How to take Mycobutin 4. Possible side effects 5. How to store Mycobutin 6. Contents of the pack and other information 1. What Mycobutin is and what it is used for Mycobutin contains the active substance rifabutin, which is an antibiotic. It is used to treat infections caused by germs (bacteria) called mycobacteria. These are bacteria which cannot be destroyed with usual antibiotics. • One of the most common mycobacterial infections is Mycobacterium tuberculosis. Mycobutin can be used in combination with other antibiotics for the treatment of tuberculosis of the lung. • Mycobutin can also be used to treat other mycobacterial infections such as Mycobacterium avium intracellulare (MAI, also known as MAC) or Mycobacterium xenopi. • People who are unable to fight infection (such as those with HIV) are more likely to be infected with mycobacteria; especially MAC.
    [Show full text]
  • Therapy and Management of Pneumocystis Jirovecii Infection
    Journal of Fungi Review Therapy and Management of Pneumocystis jirovecii Infection P. Lewis White *, Jessica S. Price and Matthijs Backx Public Health Wales Microbiology Cardiff, UHW, Heath Park, Cardiff CF14 4XW, UK; [email protected] (J.S.P.); [email protected] (M.B.) * Correspondence: [email protected]; Tel.: +44-(0)29-2074-6581; Fax: +44-(0)29-2074-2161 Received: 10 October 2018; Accepted: 11 November 2018; Published: 22 November 2018 Abstract: The rates of Pneumocystis pneumonia (PcP) are increasing in the HIV-negative susceptible population. Guidance for the prophylaxis and treatment of PcP in HIV, haematology, and solid-organ transplant (SOT) recipients is available, although for many other populations (e.g., auto-immune disorders) there remains an urgent need for recommendations. The main drug for both prophylaxis and treatment of PcP is trimethoprim/sulfamethoxazole, but resistance to this therapy is emerging, placing further emphasis on the need to make a mycological diagnosis using molecular based methods. Outbreaks in SOT recipients, particularly renal transplants, are increasingly described, and likely caused by human-to-human spread, highlighting the need for efficient infection control policies and sensitive diagnostic assays. Widespread prophylaxis is the best measure to gain control of outbreak situations. This review will summarize diagnostic options, cover prophylactic and therapeutic management in the main at risk populations, while also covering aspects of managing resistant disease, outbreak situations, and paediatric PcP. Keywords: Pneumocystis pneumonia; PcP therapy; PcP diagnosis 1. Introduction The incidence of Pneumocystis pneumonia (PcP) is rising as a result of an increase in the susceptible patient population.
    [Show full text]